Episode Details
Back to Episodes
Week in Review | Takeda's Orzeyful Approval Opens the Orexin Market — and a Payer Fight
Published 1 month, 1 week ago
Description
FDA approved Takeda's Orzeyful, a first-in-class orexin-2 agonist for narcolepsy type 1, with peak sales seen near $2B. Also: Replimune's Tudriqev wins accelerated approval with Opdivo in advanced melanoma after two rejections, Lantheus agrees to an up to $8.0 billion merger with Curium in radiopharmaceuticals, Tarsus buys Alkeus and its Stargardt disease candidate gildeuretinol for up to $800 million, reported AstraZeneca-Bristol Myers Squibb merger talks are denied, and LifeMine raises $263 million for a next-generation transplant immunosuppressant. Visit us at thepharmacloseout.com.